

## Original Article

# Altered metabolites in guinea pigs with allergic asthma after acupoint sticking therapy: New insights from a metabolomics approach



Shi-jian Xiang<sup>a,1</sup>, Meng-heng Li<sup>d,1</sup>, Chi-on Chan<sup>b,d</sup>, Qun Shen<sup>a</sup>, Si-bao Chen<sup>b,d</sup>, Bai-chao An<sup>a</sup>, Ailsa Chui-ying Yuen<sup>b,d</sup>, Wen-feng Wu<sup>a</sup>, Hok-him Tang<sup>d</sup>, Si-wei Cao<sup>a</sup>, Shi-fa Ruan<sup>a</sup>, Zhu-xian Wang<sup>a</sup>, Li-dong Weng<sup>a</sup>, Hong-xia Zhu<sup>c</sup>, Huo-ji Chen<sup>a</sup>, Melody Yee-Man Wong<sup>f</sup>, Yan Zhang<sup>e</sup>, Daniel Kam-wah Mok<sup>b,d,\*</sup>, Qiang Liu<sup>a,\*\*</sup>

<sup>a</sup> School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China

<sup>b</sup> State Key Laboratory of Chinese Medicine and Molecular Pharmacology (Incubation), Shenzhen 518057, China

<sup>c</sup> Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510315, China

<sup>d</sup> Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China

<sup>e</sup> Spine Disease Research Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China

<sup>f</sup> University Research Facility in Chemical and Environmental Analysis, The Hong Kong Polytechnic University, Hong Kong, China

## ARTICLE INFO

## Keywords:

Asthma

Metabolomics

NF-κB

Acupoint sticking therapy

Treatment of winter disease in summer prescription

## ABSTRACT

**Background:** Clinical evidence gathered in Chinese communities suggested that acupoint sticking therapy could be an alternative treatment for asthma-related diseases. However, its underlying mechanism is still poorly understood.

**Aim/hypothesis:** In this study, we aimed to investigate the mechanism of the anti-inflammatory effect of acupoint sticking application with ‘Treatment of Winter Disease in Summer’ (TWDS) prescription by using metabolomics.

**Methods:** Allergic asthma in guinea pig was sensitized and challenged by ovalbumin (OVA). Histopathological evaluation of the lung tissue was performed by hematoxylin and eosin (H&E) staining and Masson's trichrome staining. The levels of Th2 cytokine and IgE level in serum were measured using enzyme-linked immunoassay (ELISA). The mRNA expression levels of IL-4, IL-5, IL-13 and orosomucoid-like 3 (ORMDL3) were measured using quantitative reverse transcription polymerase chain reaction (RT-qPCR). Proteins of NF-κB signaling pathway were measured using western blot. The serum metabolomics profiles were obtained by using ultra-performance liquid chromatography combined with electrospray ionization quadrupole time-of-flight mass spectrometry (UPLC-ESI-QTOF-MS).

**Results:** The overall results confirmed that AST with TWDS prescription had a significant protective effect against OVA-induced allergic asthma in guinea pig. This treatment not only attenuated airway inflammation and collagen deposition in the airway, but also decreased the levels of IL-4, IL-5, IL-13 and IgE in serum. In addition, metabolomics results indicated that metabolisms of phospholipid, sphingolipid, purine, amino acid and level of epinephrine were restored back to the normal control level. Moreover, results of the gene expression of ORMDL3 in lung tissues indicated that AST using TWDS could alter the sphingolipid metabolism. Further western blotting analysis also showed that its anti-inflammatory mechanism was by decreasing the phosphorylation of p65 and IκB.

**Conclusion:** The study demonstrated that metabolomics provides a better understanding of the actions of TWDS acupoint sticking therapy on OVA-induced allergic asthma.

**Abbreviations:** AST, acupoint sticking therapy; TWDS, treatment of winter disease in summer; OVA, ovalbumin; IL-4, Interleukin-4; IL-5, Interleukin-5; IL-13, Interleukin-13; ORMDL3, orosomucoid-like 3; NF-κB, Nuclear factor-kappa B; DSP, dexamethasone sodium phosphate; IgE, Immunoglobulin E

\* Corresponding author at: Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China.

\*\* Corresponding author.

E-mail addresses: [bcdaniel@polyu.edu.hk](mailto:bcdaniel@polyu.edu.hk) (D.K.-w. Mok), [gzlq2002@163.com](mailto:gzlq2002@163.com) (Q. Liu).

<sup>1</sup> Shi-jian Xiang and Meng-heng Li contributed equally to this work.

<https://doi.org/10.1016/j.phymed.2018.09.021>

Received 5 January 2018; Received in revised form 16 June 2018; Accepted 3 September 2018

0944-7113/ © 2018 Elsevier GmbH. All rights reserved.

## Introduction

Asthma is a common chronic inflammatory respiratory disease which is generally characterized by airway hyper-responsiveness, inflammation and obstruction (Busse and Lemanske, 2001). Due to its heterogeneous syndrome encompassing a number of different subtypes and multiple phenotypes (Pavord et al., 2017), the interpretation of its underlying biological mechanism is still a challenging task. It remains a serious public health concern, affecting an estimated 300 million people worldwide (Busse and Lemanske, 2001).

Recent studies have shown that asthma is associated with immune-mediated imbalance response between T-helper type 1 (Th1) and Th2 cells. Activation of Th2 cells can help B cells to activate mast cells to release more allergic and inflammatory mediators, resulting in the elevation of the level of Immunoglobulin E (IgE) (Bosnjak et al., 2011; Larché et al., 2003). Nowadays, corticosteroids, antihistamines and leukotriene receptor antagonists are commonly used as therapeutic drugs for asthma (Chini et al., 2014). However, the side effects of these drugs have limited their use. The taking of corticosteroids in high dosages was universally found to be associated with high incidence of fractures; their long-term usage also increased the risk of myocardial infarction (Manson et al., 2009). Thus, there is an urgent need for a safe and effective alternative therapeutic treatment for asthma.

The use of acupoint sticking therapy (AST), also known as acupuncture point application therapy, in asthma management was first recorded in *Zhang Shi Yi Tong* in the Qing Dynasty (Zhang, 1990). AST is a treatment that works by externally applying herbal paste, which is made from different prescriptions according to treatment purposes, to acupoints. Traditionally, the powdered herbs are mixed with ginger, honey or water, covered with gauze and fixed with adhesive plaster before application to patients (Peng et al., 2012). The treatment is popular in many Chinese communities because it is non-invasive and it is often used as a preventive measure. The administration through skin is safer and could avoid first-pass metabolism of the therapeutic agent (s). This also gives a better control of the level of the therapeutic agent (s) in the blood stream (Delgadocharro and Guy, 2014). According to traditional Chinese medicine (TCM) theory, asthma is attributed to the obstruction of the lung by long-retained phlegm (Zhang et al., 2006). The lung, spleen and kidney are related to immunological functions and AST might regulate these organs through absorption of herbs and stimulation of the meridians. By using herbs with acrid-warm property and penetrating flavor, application of acupoint herbal paste might help warm the lung, remove phlegm, facilitate qi flow, dissolve masses and dredge collaterals.

Metabolomics aims at comprehensive characterization of endogenous metabolites and their variation in biological matrices such as plasma, urine and tissues by using high resolution nuclear magnetic resonance and mass spectrometry (Gorochategui et al., 2016; Nagana Gowda and Raftery, 2017). It is increasingly recognized as an invaluable tool to identify changes in metabolites along pathogenic development and understand the underlying mechanisms as well as influences from interventions. Metabolomics technique would provide important insights on the mechanism of AST in the treatment of asthma disease.

Our previous work had successfully demonstrated that AST using “Treating Winter Disease in Summer” (TWDS) prescription could reduce airway hyper-responsiveness and lung inflammation in ovalbumin (OVA)-sensitized animals (Xiang et al., 2016). In the current study, we aimed to investigate the underlying mechanisms of the anti-inflammatory effect of TWDS in an asthma model of guinea pig with the use of the metabolomics approach. The results obtained here indicated that application of AST using TWDS can regulate the metabolisms of phospholipid, sphingolipid, purine and amino acid. Results of the gene expression of orosomucoid-like 3 (ORMDL3) in lung tissues also indicated that AST using TWDS could alter the sphingolipid metabolism. Moreover, western blotting analysis demonstrated that its anti-

inflammatory mechanism was by decreasing the phosphorylation of p65 and IκB. This study might provide new insights for the potential use of AST using TWDS for asthma treatment.

## Materials and methods

### Preparation of TWDS patches

TWDS prescription is composed of six Chinese Material Medica (CMMs), *Sinapis Semen* (*Sinapis alba* L.), *Asari Radix et Rhizoma* (*Asarum sieboldii* Miq.), *Euphorbia kansui Radix* (*Euphorbia kansui* T.N. Liou ex T.P. Wang), *Corydalis Rhizoma* (*Corydalis yanhusuo* W.T. Wang), *Ephedra Herba* (*Ephedra sinica* Stapf) and *Scutellariae Radix* (*Scutella baicalensis* Georgi) in a ratio of 2:2:1:2:1:1. All the CMMs above were purchased from Zhixin Herbal Pharmaceutical Company Ltd. (Guangzhou, China) and authenticated by Professor Chuanming Liu from the College of Chinese Traditional Medicine, Southern Medical University (Guangzhou, China). All the herbal materials used in our study satisfy the quality requirement of the Chinese Pharmacopoeia 2015. Details of the results of the quantitative analysis and chromatographic profiles of the herbal materials used can be found in the supplementary information. All the herbs were ground into powder and mixed with ginger juice at a 2:1 ratio to make the patches (Zhong et al., 2009).

### Animals grouping, modeling and drugs administration

28 male Hartley guinea pigs of about  $275 \pm 25$  g were obtained from the Center of Laboratory Animal Science of Guangdong (License Number SCXK GD 2014–0035, Guangzhou, China). This animal study was approved by the Ethics Committee of Southern Medical University and was conducted in compliance with the animal experiment guidelines established by The Ministry of Science and Technology of the People's Republic of China. The guinea pigs were housed in an air-conditioned room kept under the experimental condition (temperature of  $25 \pm 2$  °C, humidity of  $60 \pm 5\%$  and 12/12 h light/dark cycle) with free access to food and water. All guinea pigs were acclimatized for one week.

On Days 1 and 8, twenty-one guinea pigs were sensitized by intraperitoneal injection of 100 mg OVA (Grade V, purity  $\geq 98\%$ , Sigma-Aldrich, St Louis, MO, USA) plus 1 mg of aluminum hydroxide as an adjuvant in 1 ml saline. On Days 15–28, the OVA-sensitized guinea pigs were challenged by inhaling aerosol containing 1% OVA for 10 min. On days 29, twenty-one challenged guinea pigs were randomly divided into 3 groups, OVA sensitization model group, dexamethasone sodium phosphate (DSP) treatment group and AST using TWDS treatment group. Normal control group animals (7 guinea-pigs) were sensitized and challenged with aerosolized 0.9% saline (Sagar et al., 2015; Morin et al., 2013).

The DSP treatment group received intraperitoneal injection of dexamethasone sodium phosphate (0.5 mg/kg, once daily). AST using TWDS treatment group received transdermal administration of TWDS patches (1 g/100 g, once per two days) on the acupoints of Dazhui, Feishu and Shenshu on the back. The course of treatment was 2 weeks. At the end of the treatment period (Days 43), all guinea pigs were fasted overnight, then anesthetized by intraperitoneal injection of 10% chloral hydrate anesthesia. The blood samples collected using abdominal aorta approach were centrifuged for 15 min (3000 rpm/min) to obtain the serum. Serum and lung tissues were stored at  $-80$  °C for subsequent analysis.

### Chemical and reagents

Ephedrine hydrochloride was purchased by National Institute for the Control of Pharmaceutical and Biological products of China (purity = 99.7%, Beijing, China). Sinapine thiocyanate,

tetrahydropalmatine, baicalin and asarinin were purchased from Chengdu Chroma-Biotech Co. Ltd. (purity  $\geq 98\%$ , Chengdu, China). Glycocholic acid was purchased from Steraloids (Newport, RI, USA) while norepinephrine, epinephrine, alanine, serine and valine were obtained from Sigma-Aldrich (St. Louis, MO, USA). HPLC-graded acetonitrile and methanol were obtained from Fisher Scientific (Hampton, NH, USA). Cholic acid D<sub>4</sub> and formic acid were purchased from Cambridge Isotope Laboratory Inc. (Cambridge, UK) and Sigma-Aldrich (St. Louis, MO, USA), respectively. Water was purified in-house using a Milli-Q Advantage A10 water purification system (Millipore, Bedford, MA, USA).

#### Lung histopathological examination

Guinea pig lung tissues were fixed in 4% (w/v) paraformaldehyde for 24 h and embedded in paraffin. A series of 4  $\mu\text{m}$  micro-sections were stained with Haematoxylin & Eosin (H&E) and Masson in accordance with standard protocols (Morin et al., 2011) and finally visualized under an optical microscope (LV100D, Nikon, Japan). Lung inflammation assessment was performed by semi-quantitative method (Jiao et al., 2015). The scores were graded according to three parameters: alveolar interval inflammation, inflammatory cell infiltration in bronchus, inflammatory cell infiltration in or surrounding the vasculature. Each parameter was scored as follows: 0 corresponded to no inflammation; 1 to occasional cuffing with inflammatory cells; 2 to moderate inflammatory cells and 3 to severe inflammatory cell infiltration. The total lung inflammation score was calculated by adding up the individual scores. Six sections from different guinea pigs in each group were scored. Masson's trichrome staining was used to visualize collagen deposition and fibrosis. The scores were based on the percentage of goblet cells and were calculated as follows: 0: none; 1:  $\leq 25\%$ ; 2: 25 – 50%; 3: 50 – 75%; and 4:  $\geq 75\%$  goblet cells (Ma et al., 2016). Six sections from different guinea pigs in each group were examined and their scores were assessed by two experienced researchers, who were blinded to the information of samples.

#### Determination of cytokines and IgE level

The levels of interleukin 4 (IL-4), IL-5, IL-13 and IgE in the serum of guinea pigs were determined using the enzyme-linked immunosorbent assay (ELISA) kit from CUSABIO Biotech (Wuhan, China) according to the manufacturer's instructions. All tests were performed in duplicate. Optical densities were measured at 450 nm by a microplate reader.

#### Quantitative reverse transcription polymerase chain reaction (RT-qPCR)

IL-4, IL-5, IL-13 and orosomucoid-like 3 (ORMDL3) mRNA levels in lung tissues were determined by RT-qPCR. Total lung RNA was extracted with TRIzol (Sigma-Aldrich, St Louis, MO, USA) and reverse-transcribed to cDNA according to the manufacturer's instructions (Takara, Dalian, China). RT-qPCR was performed on the cDNA samples according to the instructions of the SYBRs Premix Ex Tap™ II (Takara, Dalian, China). The reaction conditions were as follows: 95 °C for 30 s, followed by 45 cycles of denaturation at 95 °C for 5 s and 60 °C for 34 s. The used primers (Sangon Biotech, Shanghai, China) were listed in Table 1. The expression level of each gene was normalized to

endogenous GAPDH expression level, and reported as fold-change relative to normal control group.

#### Western blot analysis

Lung tissues from guinea pigs were lysed in RIPA buffer containing PMSF and phosphatase inhibitors (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) followed by quick freezing. Proteins were extracted by a kit according to the manufacturer's protocol (Beyotime Biotech Inc, Nanjing, China) and the protein concentrations were measured by a bicinchoninic acid protein concentration assay kit. The proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride membranes (0.45 mm, Millipore, Boston, MA, USA). Non-specific sites were blocked with 5% bovine serum albumin (BSA) in tris-buffered saline containing 0.1% Tween 20 (TBST) for 2 h and the blots were incubated with specific primary antibodies, including anti-p65 NF- $\kappa$ B, anti-phospho-p65 NF- $\kappa$ B, anti-I $\kappa$ B, anti-phospho-I $\kappa$ B and GAPDH proteins antibodies (1:1000, Cell Signaling Technology, Boston, MA, USA) for 12 h at 4 °C. The membranes were rinsed 3 times with TBST for 5 min and incubated for 1 h at a ratio of 1:1000 to secondary immunoglobulin conjugated horseradish peroxidase (Sigma-Aldrich, St. Louis, MO, USA) at 25 °C. The membranes were then extensively washed with TBST, and detected by an enhanced chemiluminescence method (ECL kit, Millipore, USA). Image of blot immune-staining was captured and analyzed using Image J software to determine the phosphorylated to total protein ratio.

#### Chemical analysis of TWDS prescription

##### Extraction procedure

Accurately weighed 0.1 g TWDS prescription powder samples were sonicated with 1 ml methanol for 30 min. Then, the mixture was centrifuged at 14,000 rpm at 4 °C for 15 min. The solution was filtered through 0.45  $\mu\text{m}$  membrane filters prior to chemical analysis.

##### Ultra performance liquid chromatography coupled with electrospray ionization orbitrap mass spectrometry (UPLC-ESI-Orbitrap-MS)

UPLC-ESI-Orbitrap-MS analysis was performed on Orbitrap Fusion Lumos Tribrid Mass Spectrometer (Thermo Fisher Scientific, U.S.A.) with UPLC (ACQUITY UPLC System, Waters, USA). An UPLC C18 analytical column (2.1 mm  $\times$  100 mm, I.D. 1.8  $\mu\text{m}$ , ACQUITY UPLC®HSS T3, Waters, U.S.A.) was used for separation at 40 °C. The mobile phase was a mixture of water (A) and acetonitrile (B), both containing 0.1% (v/v) formic acid, with a linear gradient elution as follows: 0–1 min, 98% A; 1–5 min, 80% A; 5–13 min, 71% A; 13–17 min, 20% A, 17–18 min, 98% A, 18–20 min, 98% A. The injection volume was 3  $\mu\text{l}$ . The flow rate was set at 0.30 ml/min.

Heated electrospray ionization was used in both positive and negative ion modes. The operation parameters were as follows: spray voltage static (positive ion 3600 V, negative ion 2300 V) sheath gas flow rate 20 units, auxiliary gas flow rate 10 units, sweep gas 10 units, ion transfer tube temperature 300 °C, vaporizer temperature 200 °C. The mass spectra were acquired in full scan mode from 100 to 1200 in mass to charge ratio ( $m/z$ ) with a mass resolution of 120,000, RF Lens 30%. The mass spectra were collected in centroid mode. Data were evaluated by Quan/Qual Browser and Xcalibur 4.0 (Thermo Fisher Scientific, U.S.A.)

#### Metabolomics

##### Quality control sample preparation method

An aliquot of 150  $\mu\text{l}$  of each serum sample was pooled, vortexed and aliquoted to provide a quality control (QC) sample, and kept at  $-80$  °C until use. QC samples went through the extraction protocols as described below as similar to all other samples. Before the start of

**Table 1**  
The sequence of primes for RT-qPCR analysis.

| Gene   | Forward prime(5'–3')  | Reverse prime(5'–3')   |
|--------|-----------------------|------------------------|
| IL-4   | GGAGAAGAGTCCCTGTGCGG  | CGGAGGTAGGCTGTATGGTGC  |
| IL-5   | GCAGTTGGGTTTGCTGGCTCT | TCGCTCCTCCCGCATTT      |
| IL-13  | CCGTGGTCCCTTGCTCTTGC  | GGTCTTCTGATCCTGGGTGATG |
| ORMDL3 | CAGCGAGGTGAACCTAACA   | CTGAGGCAACTGGGAATGA    |
| GAPDH  | AAGGTCGGAGTGAACGGATT  | TGGGGCTAAGCAGTTGGTG    |

chemical analysis, five repeated injections of the same QC sample were used to verify the working condition the instruments. Afterwards, the QC sample was injected to monitor the stability of the instruments after every five-sample run.

#### Sample preparation

100  $\mu$ l serum from each sample was mixed with 300  $\mu$ l cold methanol, which contained 5 ppm of cholic acid D<sub>4</sub> as internal standard, and then vortexed for 30 s. The mixture was cooled in a freezer at  $-20^{\circ}\text{C}$  for one hour prior to centrifugation at 14,000 rpm under  $4^{\circ}\text{C}$  for 15 min. 320  $\mu$ l supernatant was dried with nitrogen gas and reconstituted in 100  $\mu$ l 50% methanol in water followed by centrifugation at 14,000 rpm under  $4^{\circ}\text{C}$  for 10 min. The supernatant was obtained for subsequent UPLC-ESI-QTOF-MS analysis.

#### Ultra-performance liquid chromatography combined with electrospray ionization quadrupole time-of-flight mass spectrometry (UPLC-ESI-QTOF-MS) condition

4  $\mu$ l aliquot was injected into a Waters ACQUITY UPLC system. The separation was performed on a Waters ACQUITY UPLC HSS T3 column (2.1 mm  $\times$  100 mm, 1.8  $\mu$ m) with HSS T3 pre-column (2.1 mm  $\times$  5 mm, 1.8  $\mu$ m, Waters Corporation, Milford, MA). The mobile phase consisted of combinations of A (0.1% formic acid in water, v/v) and B (0.1% formic acid in acetonitrile, v/v) at a flow rate of 0.3 ml/min with elution gradient as follows: 0–1 min, 5% B; 5 min, 40% B; 8 min, 50% B; 16 min, 65% B; 17–20 min, 95% B. A 3-min post-run time was set to fully equilibrate the column. Column temperature and sample chamber temperature were  $40^{\circ}\text{C}$  and  $6^{\circ}\text{C}$  respectively.

MS was performed on a Waters SYNAPT G2 Q-IM-TOF HDMS system (Waters, Milford, USA) operating in an ESI in both positive and negative modes. Nitrogen was used as nebulization and cone gas. The nebulization gas was set to 550 L/h at a temperature of  $400^{\circ}\text{C}$ , and the cone gas was set to 40 L/h. The source temperature was set at  $120^{\circ}\text{C}$ . The capillary voltages in positive and negative ion modes were 3.0 kV and 2.2 kV, respectively. The sampling and extraction cone voltages were 40 V and 4.0 V, respectively. The data acquisition rate was set to 1 s with a 0.024 s interscan delay. Data between  $m/z$  50 to 1000 were recorded in the centroid mode. For accurate mass acquisition, a lock-mass of leucine enkephalin at a concentration of 10 ng/ml was used via a lock spray interface at a flow rate of 5  $\mu$ l/min, 3.0 eV trap collision energy, 2.2 kV capillary energy and 40 V cone voltage, monitoring for positive ion mode ( $[\text{M} + \text{H}]^{+}$ : 556.2771) and negative ion mode ( $[\text{M} - \text{H}]^{-}$ : 554.2615) to ensure accuracy during the MS analysis. MS/MS analysis was carried out to study the structure of potential biomarkers. In this section, argon was employed as collision gas and the collision energy was set between 20 and 50 eV according to the situation.

#### Data processing and analysis

The peak picking and alignment of all raw UPLC-MS data were conducted by Progenesis QI software (Nonlinear Dynamics, Newcastle upon Tyne, United Kingdom) in both ionization modes. Data were imported in the following setting prior to peak picking: resolution (full width at half maximum), 20,000; retention time limit, 0.3–20 min; data type, centroided while other settings were set at default. All ion abundance was normalized by internal standard of its own sample to generate a data matrix that consisted of the retention time,  $m/z$  value, and the normalized ion abundance.

Quality screening was done by filtering out those metabolites whose relative standard deviation was greater than 30% in quality control samples to reduce the contribution of unstable peaks and eliminate noise from the dataset.

The resultant data matrices were introduced to Extended Statistical tool EZinfo v2.0 software (Umetrics AB, Sweden) for multivariate analysis. The data were scaled to unit variance for principal component analysis (PCA) to give an overview of the repeatability of QC samples.

The QC samples with high repeatability should cluster together in the score plot of PCA. The samples excluding QC samples were pareto-scaled for partial least squares-discriminant analysis (PLS-DA) and orthogonal partial least squares - discriminant analysis (OPLS-DA). Potential markers of interest were extracted from the variable importance in the projection (VIP) values (threshold of  $\text{VIP} \geq 1$ ) and the location in S-loading plot of OPLS-DA based on their contribution to the variation and correlation in the data set. The markers were identified by LC-MS/MS and matched with the METLIN (<http://metlin.scripps.edu>), the Mass Bank (<http://www.massbank.jp/>) and the Human Metabolome Databases ([www.hmdb.ca](http://www.hmdb.ca)) and/or confirmed by literatures and authentic standards based on retention times, mass fragmentation pattern and accurate masses (mass error  $< 5$  ppm).

#### Statistics

All data were shown as the mean  $\pm$  standard deviation (SD), and one-way ANOVA was used to calculate significant differences between the groups. Statistical differences were considered significant if the  $P$  value was less than 0.05. All statistical analyses were performed using SPSS 19.0 (SPSS Inc., USA.).

#### Results

##### Chemical constituents of TWDS prescription

Quantitative analysis of ephedrine hydrochloride, sinapine thiocyanate, tetrahydropalmatine, baicalin and asarinin in raw herbal materials of Ephedra Herba, Sinapis Semen, Corydalis Rhizoma, Scutellariae Radix and Asari Radix et Rhizoma was carried out respectively, and all samples fulfilled the requirement stipulated in the 2015 Chinese Pharmacopoeia (supplementary Table 1, supplementary Fig. 1). In addition, 49 components, including organic acids, phenolic and its glycosides and alkaloids, were tentatively identified by UPLC-ESI-Orbitrap-MS after comparison of the accurate  $m/z$  and mass fragmentation pattern with literatures as well as online database. The base peak chromatogram of extract of TWDS prescription was depicted in Fig. 1 and a summary of phytochemicals detected by UPLC-ESI-Orbitrap-MS was shown in Table 2.

##### Pathology of lung tissue inflammation

Histological analysis was performed on lung sections derived from guinea pigs and the results were presented in Fig. 2. Lung tissues with H&E staining revealed that an extensive hyperplasia and hypertrophy in goblet cells was visualized in the OVA group. The submucosa also showed evidence of infiltration of inflammatory cells together with smooth muscle thickening. A number of inflammatory cells, including lymphocytes and eosinophilic granulocytes, were found in the alveolar septa around the bronchus in the OVA sensitization model group when compared with the normal control group (Fig. 2(a)). The inflammation score of the OVA group was  $7.7 \pm 1.21$  while that score of the normal control group was  $2.0 \pm 0.89$  (Fig. 2(b)). Normal histological structure and minimal inflammation in the normal control group were clearly indicated. After administration of DSP and AST, infiltration of inflammatory cells in lung tissue was reduced. Pulmonary hyperemia, edema phenomenon, the extent of bronchial wall and alveolar wall thickening were alleviated and the inflammation scores of DSP and AST treatment were  $4.2 \pm 1.17$  and  $4.7 \pm 1.21$ , respectively ( $p < 0.01$ ) (Fig. 2(a) & (b)). The results indicated that airway fibrosis was significantly ameliorated after both administration of DSP and AST with TWDS.

##### Histological analysis performed on lung sections with Masson staining

Lung tissues with Masson staining among different groups for the




Fig. 1. The base peak chromatogram (BPC) of the methanol extract of by UPLC-orbitrap-ESI-MS in the positive (a) and negative (b) ion modes.

assessment of collagen deposition were shown in Fig. 2(a) & (c). It was demonstrated that there was minimal collagen fibrosis in the normal control group, with a score of  $0.50 \pm 0.55$ . However, extensive collagen fibrosis in the airway was found in the OVA model group, with a score of  $3.7 \pm 0.52$ . In comparison with the OVA model group, the collagen deposition area around the airway and epithelium loss were reduced significantly in both the DSP ( $1.8 \pm 0.75$ ) and AST using TWDS ( $2.0 \pm 0.89$ ) treatment groups.

#### Effect of AST using TWDS treatment on IL-4, IL-5, IL-13 & total IgE in serum and IL-4, IL-5, IL-13 & ORMDL3 in lung tissue

Fig. 3(a) and (b) summarized the effect of AST using TWDS treatment on IL-4, IL-5, IL-13 and total IgE in serum and lung tissue, respectively. The levels of IL-4, IL-5 and IL-13 in serum were increased significantly in the OVA model group compared with those in the normal control group ( $P < 0.01$ ). With the administration of DSP and AST using TWDS treatment for two weeks, the levels of IL-4, IL-5 and IL-13 in serum were significantly decreased in comparison with those of the OVA model group ( $P < 0.01$  and  $P < 0.05$ ). Similarly, both administration of DSP and treatment of AST using TWDS groups exhibited significantly inhibited levels of IgE when compared with those of the OVA model group ( $P < 0.01$ ).

The results of RT-qPCR for determining the expression levels of various genes in lung tissues were shown in Fig. 3(c) and (d). There was

a substantial increase in IL-4, IL-5 and IL-13 gene expression in the guinea pigs with OVA-induced asthma. Both administration of DSP and AST using TWDS treatment exhibited remarkable downregulation of IL-4, IL-5 and IL-13 mRNA expressions compared with the OVA model group. Similarly, the gene level of ORMDL3 was significantly increased in the OVA-induced guinea pigs, while it was decreased distinctly after administration of DSP and AST using TWDS treatment in comparison with the OVA model group.

#### Effect of TWDS prescription acupoint application on NF- $\kappa$ B activation

NF- $\kappa$ B signaling is one of the recognized cytoprotective targets that mediates inflammation. Thus, the expression levels of proteins related to NF- $\kappa$ B pathway including p65 NF- $\kappa$ B (p65), phosphorylated-p65 NF- $\kappa$ B (p-p65), I $\kappa$ B and phosphorylated-I $\kappa$ B (p-I $\kappa$ B) were examined using Western blot analysis. As shown in Fig. 4, the ratios of p-p65/p65 and p-I $\kappa$ B/I $\kappa$ B were significantly higher in the OVA model group compared with those in the normal control group ( $p < 0.01$ ). However, the ratios of p-p65/p65 and p-I $\kappa$ B/I $\kappa$ B were significantly decreased in both administration of DSP ( $p < 0.01$ ) and treatment of AST using TWDS groups ( $p < 0.05$ ).

#### Stability of metabolomics platform

The stability of UPLC-ESI-QTOF-MS detection was assessed by

**Table 2**  
Compounds identified in TWDS prescription by UPLC-ESI-Orbitrap-MS.

| No. | Retention time | Molecular formula                                             | [M + H] <sup>+</sup> (m/z)<br>(mass accuracy)(ppm) | [M – H] <sup>–</sup> (m/z)<br>(mass accuracy)(ppm) | Identification                                              | Origins                                     |
|-----|----------------|---------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|-------------------------------------------------------------|---------------------------------------------|
| 1   | 3.27           | C <sub>8</sub> H <sub>13</sub> NO                             | 152.1065 (3.29)                                    |                                                    | Nor(pseudo)ephedrine                                        | Ephedra sinica (Lv et al., 2015)            |
| 2   | 3.86           | C <sub>10</sub> H <sub>15</sub> NO                            | 166.1221 (3.01)                                    |                                                    | (pseudo)ephedrine                                           | Ephedra sinica (Lv et al., 2015)            |
| 3   | 4.07           | C <sub>28</sub> H <sub>46</sub> N <sub>4</sub> O <sub>4</sub> | 493.2795 (2.84)                                    |                                                    | Ephedradine A                                               | Ephedra sinica (Lv et al., 2015)            |
| 4   | 4.17           | C <sub>11</sub> H <sub>17</sub> NO                            | 180.1376 (3.89)                                    |                                                    | Methyl(pseudo)ephedrine                                     | Ephedra sinica (Lv et al., 2015)            |
| 5   | 4.64           | C <sub>15</sub> H <sub>14</sub> O <sub>6</sub>                | 291.0854 (3.09)                                    |                                                    | Catechin                                                    | Ephedra sinica (Lv et al., 2015)            |
| 6   | 4.71           | C <sub>8</sub> H <sub>12</sub> N <sub>2</sub>                 | 137.1069 (2.92)                                    |                                                    | Tetramethylpyrazine                                         | Ephedra sinica (Lv et al., 2015)            |
| 7   | 5.16           | C <sub>10</sub> H <sub>10</sub> O <sub>4</sub>                | 195.0646 (3.08)                                    |                                                    | Kakuoil                                                     | Asarum sieboldii (Wen et al., 2014)         |
| 8   | 6.05           | C <sub>15</sub> H <sub>12</sub> O <sub>7</sub>                |                                                    | 303.0509(0.33)                                     | (2R,3R)-3,5,7,2',6-Pentahydroxyglavanone                    | Scutellaria Baicalensis (Qiao et al., 2016) |
| 9   | 6.61           | C <sub>26</sub> H <sub>28</sub> O <sub>13</sub>               |                                                    | 547.1457(–3.84)                                    | Chrysin 6-C-pen-8-C-hex                                     | Scutellaria Baicalensis (Qiao et al., 2016) |
| 10  | 6.74           | C <sub>64</sub> H <sub>20</sub> O <sub>12</sub>               |                                                    | 463.0887(–1.08)                                    | Carthamidin 7-O-glucuronide                                 | Scutellaria Baicalensis (Qiao et al., 2016) |
| 11  | 6.86           | C <sub>29</sub> H <sub>36</sub> O <sub>15</sub>               |                                                    | 623.2003(–3.53)                                    | Acteoside                                                   | Scutellaria Baicalensis (Qiao et al., 2016) |
| 12  | 6.89           | C <sub>11</sub> H <sub>12</sub> O <sub>5</sub>                |                                                    |                                                    | Sinapic acid                                                | Semen Sinapis (Liu et al., 2003)            |
| 13  | 6.99           | C <sub>23</sub> H <sub>24</sub> O <sub>13</sub>               |                                                    | 507.1145(–0.2)                                     | Viscidlin III 6'-O-β-D-glucoside                            | Scutellaria Baicalensis (Qiao et al., 2016) |
| 14  | 7.12           | C <sub>20</sub> H <sub>28</sub> NO <sub>4</sub>               | 342.17(3.51)                                       |                                                    | Corypalmine                                                 | Rhizoma Corydalis (Zheng et al., 2017)      |
| 15  | 7.30           | C <sub>29</sub> H <sub>38</sub> N <sub>4</sub> O <sub>5</sub> | 523.2933 (–3.44)                                   |                                                    | Ephedradine B/D                                             | Ephedra sinica (Lv et al., 2015)            |
| 16  | 7.36           | C <sub>21</sub> H <sub>25</sub> NO <sub>4</sub>               | 356.1845(0.00)                                     |                                                    | Glaucone                                                    | Scutellaria Baicalensis (Qiao et al., 2016) |
| 17  | 7.46           | C <sub>21</sub> H <sub>20</sub> O <sub>9</sub>                |                                                    | 415.1032(0.72)                                     | Chrysin-8-C-glucoside                                       | Scutellaria Baicalensis (Qiao et al., 2016) |
| 18  | 7.48           | C <sub>29</sub> H <sub>36</sub> O <sub>15</sub>               |                                                    | 623.1981(0)                                        | Acteoside isomer                                            | Rhizoma Corydalis (Zheng et al., 2017)      |
| 19  | 7.89           | C <sub>20</sub> H <sub>19</sub> NO <sub>5</sub>               |                                                    |                                                    | Protopine                                                   | Scutellaria Baicalensis (Qiao et al., 2016) |
| 20  | 8.15           | C <sub>21</sub> H <sub>20</sub> O <sub>9</sub>                |                                                    | 415.1033(0.48)                                     | Chrysin 6-C-glucoside                                       | Scutellaria Baicalensis (Qiao et al., 2016) |
| 21  | 8.50           | C <sub>20</sub> H <sub>20</sub> O <sub>6</sub>                |                                                    |                                                    | Pluviatolol                                                 | Asarum sieboldii (Wen et al., 2014)         |
| 22  | 8.52           | C <sub>20</sub> H <sub>18</sub> O <sub>6</sub>                |                                                    | 353.1031(1.42)                                     | Asarinin                                                    | Asarum sieboldii (Wen et al., 2014)         |
| 23  | 8.76           | C <sub>21</sub> H <sub>23</sub> NO <sub>5</sub>               | 370.1649(3.51)                                     |                                                    | Alloxyptopins                                               | Rhizoma Corydalis (Zheng et al., 2017)      |
| 24  | 8.91           | C <sub>21</sub> H <sub>25</sub> NO <sub>4</sub>               | 356.1856(3.09)                                     |                                                    | Tetrahydropalmatine                                         | Rhizoma Corydalis (Zheng et al., 2017)      |
| 25  | 9.17           | C <sub>16</sub> H <sub>14</sub> O <sub>6</sub>                |                                                    | 301.0714(1)                                        | Trihydroxy-methoxyflavanone                                 | Scutellaria Baicalensis (Qiao et al., 2016) |
| 26  | 9.21           | C <sub>19</sub> H <sub>14</sub> NO <sub>4</sub>               | 320.0907(3.12)                                     |                                                    | Coptisine                                                   | Rhizoma Corydalis (Zheng et al., 2017)      |
| 27  | 9.87           | C <sub>21</sub> H <sub>19</sub> NO <sub>4</sub>               | 240.1533 (2.94)                                    |                                                    | Tetrahydroberberine                                         | Rhizoma Corydalis (Zheng et al., 2017)      |
| 28  | 10.20          | C <sub>22</sub> H <sub>27</sub> NO <sub>4</sub>               | 370.2000(3.24)                                     |                                                    | Corydaline                                                  | Rhizoma Corydalis (Zheng et al., 2017)      |
| 29  | 10.33          | C <sub>21</sub> H <sub>22</sub> NO <sub>4</sub>               | 352.1532(0.57)                                     |                                                    | Palmatine / Dehydrocorybulbine                              | Rhizoma Corydalis (Zheng et al., 2017)      |
| 30  | 10.84          | C <sub>31</sub> H <sub>40</sub> O <sub>15</sub>               |                                                    | 651.2308(–2.15)                                    | Cistanoside D isomer                                        | Scutellaria Baicalensis (Qiao et al., 2016) |
| 31  | 10.89          | C <sub>21</sub> H <sub>20</sub> O <sub>11</sub>               |                                                    | 447.0933(–1.79)                                    | 5,7,2',6'-Tetrahydroxyflavone 2'-O-β-d-glucoside            | Scutellaria Baicalensis (Qiao et al., 2016) |
| 32  | 11.29          | C <sub>21</sub> H <sub>18</sub> O <sub>11</sub>               |                                                    | 445.0776(–3.37)                                    | Baicalin 7-glucuronide                                      | Scutellaria Baicalensis (Qiao et al., 2016) |
| 33  | 11.41          | C <sub>21</sub> H <sub>22</sub> NO <sub>4</sub>               |                                                    |                                                    | Palmatine / Dehydrocorybulbine                              | Rhizoma Corydalis (Zheng et al., 2017)      |
| 34  | 11.58          | C <sub>20</sub> H <sub>18</sub> NO <sub>4</sub>               |                                                    |                                                    | Berberine                                                   | Rhizoma Corydalis (Zheng et al., 2017)      |
| 35  | 11.73          | C <sub>22</sub> H <sub>20</sub> O <sub>12</sub>               |                                                    | 475.0883(–0.21)                                    | Trihydroxy-methoxyflavanone O-gluA                          | Scutellaria Baicalensis (Qiao et al., 2016) |
| 36  | 12.27          | C <sub>22</sub> H <sub>22</sub> O <sub>11</sub>               |                                                    | 459.0948(–3.27)                                    | Baicalin O-gluA methyl ester                                | Scutellaria Baicalensis (Qiao et al., 2016) |
| 37  | 12.45          | C <sub>22</sub> H <sub>20</sub> O <sub>12</sub>               |                                                    | 475.0881(0.21)                                     | Trihydroxy-methoxyflavanone O-gluA                          | Scutellaria Baicalensis (Qiao et al., 2016) |
| 38  | 12.64          | C <sub>22</sub> H <sub>24</sub> NO <sub>4</sub>               |                                                    |                                                    | Dehydrocorydaline                                           | Rhizoma Corydalis (Zheng et al., 2017)      |
| 39  | 13.14          | C <sub>22</sub> H <sub>22</sub> O <sub>11</sub>               |                                                    | 459.0948(–3.27)                                    | Wogonoside                                                  | Scutellaria Baicalensis (Qiao et al., 2016) |
| 40  | 13.71          | C <sub>23</sub> H <sub>22</sub> O <sub>12</sub>               |                                                    | 489.1039(–0.2)                                     | 5,7-Dihydroxy-8,2'-dimethoxyflavone                         | Scutellaria Baicalensis (Qiao et al., 2016) |
| 41  | 14.05          | C <sub>23</sub> H <sub>24</sub> O <sub>12</sub>               |                                                    | 491.1192(0.61)                                     | 5,2',6'-Dihydroxy-7,8-dimethoxyflavone 412'-O-β-D-glucoside | Scutellaria Baicalensis (Qiao et al., 2016) |
| 42  | 14.81          | C <sub>16</sub> H <sub>12</sub> O <sub>6</sub>                |                                                    | 299.0559(0.67)                                     | Trihydroxy-methoxyflavone                                   | Scutellaria Baicalensis (Qiao et al., 2016) |
| 43  | 15.16          | C <sub>15</sub> H <sub>10</sub> O <sub>5</sub>                |                                                    | 269.0455(–2.23)                                    | Baicalin                                                    | Scutellaria Baicalensis (Qiao et al., 2016) |
| 44  | 16.23          | C <sub>16</sub> H <sub>12</sub> O <sub>5</sub>                |                                                    | 283.0619(2.47)                                     | Wogonin                                                     | Scutellaria Baicalensis (Qiao et al., 2016) |
| 45  | 16.23          | C <sub>15</sub> H <sub>10</sub> O <sub>4</sub>                |                                                    | 253.0513(2.77)                                     | Chrysin                                                     | Scutellaria Baicalensis (Qiao et al., 2016) |
| 46  | 16.52          | C <sub>17</sub> H <sub>26</sub> O <sub>4</sub>                |                                                    | 293.1758(–0.68)                                    | 6-gingerol                                                  | Zingiber officinale (Wu et al., 2018)       |
| 47  | 17.04          | C <sub>21</sub> H <sub>34</sub> O <sub>4</sub>                |                                                    | 351.2553(3.7)                                      | 10-gingerol                                                 | Zingiber officinale (Wu et al., 2018)       |
| 48  | 17.74          | C <sub>41</sub> H <sub>47</sub> O <sub>15</sub>               |                                                    | 794.3018(3.78)                                     | Kansuine D                                                  | Euphorbia kansui (Shu et al., 2016)         |
| 49  | 17.75          | C <sub>17</sub> H <sub>24</sub> O <sub>4</sub>                |                                                    | 293.1747(3.75)                                     | 6-dehydro-6-geringol                                        | Zingiber officinale (Wu et al., 2018)       |

\*Marker confirmed by comparing the database and literatures (Lv et al., 2015; Shu et al., 2016; Qiao et al., 2016; Wen et al., 2014; Zheng et al., 2017; Wu et al., 2018; Liu et al., 2003)




**Fig. 2.** (a) H&E and Masson's trichrome staining of lung sections of guinea pigs with magnification (200 ×); (b) Histological semi-quantitative scores of lung inflammation; (c) Histological semi-quantitative scores of collagen deposition. Each bar represents the mean ± SEM ( $n = 6$ ). # $P < 0.05$  and ## $P < 0.01$  vs the normal control group. \* $P < 0.05$  and \*\* $P < 0.01$  vs OVA group.

multiple injections of the same pooled QC sample with a known concentration of an internal standard being added throughout the whole experimental run. Principle component analysis (PCA) score plot was used to evaluate the stability of the analytical instruments. Fig. 5(a) showed the QC sample injections of inter-day experiments were clustered together in the PCA score plots. In addition, the coefficients of variation of internal standard were 10.2% and 8.0% in positive and negative ionization modes, respectively. Both results demonstrated that high reproducibility was achieved across the runs. This also ensured those changes among the different groups observed from the statistical analysis were related to the different interventions.

#### Effects on metabolite changes

In the data collected from UPLC-MS, peak extraction by Progenesis QI obtained 3734 and 2875 peaks in all samples under positive and negative modes, respectively. After quality screening (QC's CV ≤ 30%), 2402 and 1955 metabolite features were detected at positive and negative modes, respectively.

Changes in metabolites in the serum were investigated by using OPLS-DA and Fig. 5(b) showed clear separation between the normal control and the OVA model groups. Metabolites with significant contribution to the differentiation of the two groups by OPLS-DA were identified by their variable importance in the projection (VIP) values (threshold of VIP > 1) and the location in S-loading plot.

To reveal the underlying action of both administration of DSP and treatment of AST using TWDS, PLS-DA was applied and the results were depicted in Fig. 5(c). It was clearly indicated that there was obvious separation among the normal control, OVA, DSP and AST using TWDS groups. 594 and 500 metabolites features detected at positive and negative modes respectively were obtained and some highlighted potential metabolites were listed in Table 3. Their identities were tentatively confirmed by comparison with external standard, MS-MS data or online databases.

#### Discussion

Currently, corticosteroid drugs such as dexamethasone sodium




**Fig. 3.** (a) Levels of cytokines of IL-4, IL-5, IL-13 in serum; (b) Levels of IgE in different groups of serum; (c) gene levels of IL-4, IL-5 and IL-13 in lung tissue; (d) gene levels of ORMDL3 in lung tissue ( $n = 6$ ). Compared with the normal control group, <sup>#</sup> $P < 0.05$  and <sup>##</sup> $P < 0.01$ ; compared with the normal control group, <sup>\*</sup> $P < 0.05$  and <sup>\*\*</sup> $P < 0.01$  vs OVA model group.

phosphate (DSP) remain the first-line treatment for patients with chronic asthma. However, there are many side effects such as hyperglycemia, adrenal suppression and osteoporosis when high dosages are applied (Sarnes et al., 2011). In the present study, the beneficial effects of AST using TWDS on the skin tissue of guinea pigs were studied by using an OVA-induced asthma model, which has been utilized extensively for modeling human asthma (Nials and Uddin, 2008). OVA was served as the source of allergen in this work, and a Type 1 immune response was triggered after sensitization and aerosol challenge. A Th2-skewed response characterized by Th2 cytokines such as interleukin-4 (IL-4), IL-5, and IL-13 tends to mediate the production of ovalbumin-specific immunoglobulin type E (IgE) by B cells (Chini et al., 2014; Manson et al., 2009). It is one of the strong risk factors for developing asthma, in which IL-4 is important for allergic sensitization and IgE production; while IL-5 is crucial for eosinophil survival and IL-13 has pleiotropic effects in the lungs (Gilfillan and Tkaczyk, 2006; Finkelman et al., 2010).

Our experimental results were consistent with clinical observations that there were significant differences in the level of IL-4, IL-5, IL-13 and IgE between the OVA model group and the normal control group (Renauld, 2001). The reduction in serum level of IL-4, IL-5, IL-13 and

IgE as a result of administration of DSP and treatment of AST using TWDS certainly played an important role in the therapeutic effects of these intervention.

Results of histopathological examination of the lung tissue using H&E also indicated that there was excessive infiltration of inflammatory cells, mostly eosinophils and lymphocytes in the OVA model group compared with the normal control group. In addition, both administration of DSP and treatment of AST using TWDS could lower cell accumulation in the peribronchiolar, perivascular and alveolar regions and result in decrease in lung inflammation scores, compared with the OVA model group. Overexpression of Th2 cytokines and IgE is known to enhance collagen deposition in the lung tissue (Busse and Lemanske, 2001). Moreover, airway mucus was mainly secreted by airway goblet cells, and its proliferations contributed to the pathologic changes in airway remodeling and exacerbation of asthma (Rogers, 2007; Davis and Dickey, 2015). Masson staining results showed that sub-epithelial collagen deposition (blue stain) arisen in the airway was significantly reduced in both the administration of DSP and treatment of AST using TWDS groups. This implied that treatment of AST using TWDS might be significant as a new anti-allergic agent for asthma management.




**Fig. 4.** Protein levels of p65 NF-κB, p-p65 NF-κB, IκB, p-IκB in lung tissue. (a) Typical Western blot; (b) Semi-quantitative analysis of lung homogenate western blotting. Compared with the normal control group, <sup>#</sup> $P < 0.05$  and <sup>##</sup> $P < 0.01$ ; compared with the normal control group, <sup>\*</sup> $P < 0.05$  and <sup>\*\*</sup> $P < 0.01$  vs OVA model group.


The allergic immune response of asthma is a complex process, and the pathophysiological responses, including lung eosinophilic inflammation, smooth muscle contraction and increased mucus production, result in airway obstruction and eventually lung damage (Bosnjak et al., 2011). From our metabolomics data, the level of leukotriene B<sub>4</sub>, which is a pro-inflammatory mediator produced from leukocytes, was significantly increased in the OVA model group compared with the normal control group. Other anti-inflammatory phospholipid metabolites such as lysoPC (18:0) and lysoPC(20:3) in the OVA model group were also significantly decreased, compared with the normal control group. However, with the administration of DSP and treatment of AST using TWDS, the level of leukotriene B<sub>4</sub> was down-regulated back to the normal control while the levels of lysoPC (18:0) and lysoPC (20:3) were upregulated back to the normal control. A similar trend was obtained in the fatty acid metabolism. Levels of anti-inflammatory metabolites such as C20:5 and C22:5 (DPA) in the OVA model were decreased significantly, compared with the normal control group. At the same time, both metabolites were upregulated to the normal level in the AST using TWDS treatment group.

Epinephrine, also known as adrenaline, is a naturally occurring metabolite in the human body and is used to relax the bronchial smooth muscle for the treatment of asthma. It has been reported that epinephrine levels in asthma patients do not increase as rapidly as needed to alleviate bronchoconstriction (Barnes et al., 1980; Aalderen van et al., 1991). Thus, it has been proposed that this weak increase in circulating epinephrine is an important factor in the pathogenesis of asthma (Bates et al., 1994). In this study, the measured level of epinephrine in the OVA model group was significantly higher than that of the normal control group, an observation that was consistent with previous literatures. With the treatment of AST using TWDS and administration of DSP, the level of epinephrine in serum of both groups was downregulated.

Xanthine is a key metabolite in purine metabolism and has been reported to have close relationship with neutrophilic inflammation of chronic obstructive pulmonary disease (Esther et al., 2015). Increased uric acid (end product of purine metabolism) levels of bronchoalveolar lavage fluids (BALF) in the airways of allergen-challenged asthmatic

patients and mice were reported (Esther et al., 2015). In this study, the serum level of xanthine in the OVA model was decreased significantly compared with that of the normal control group. Disturbance in purine metabolism due to asthma was observed and more xanthine might be converted into uric acid and secreted out in BALF. A recent study reported that the level of taurine, phenylalanine and xanthine in serum was decreased slightly in mild asthma patients (Reinke et al., 2017). With treatment of AST using TWDS, the level of xanthine in serum was upregulated to the level of the normal control group. It has been reported that xanthine could be used as a bronchodilator to treat asthma (Seddon et al., 2006). However, administration of DSP did not regulate it back to the normal level.

Sphingolipid metabolites play an important role in the signaling events that influence cell behavior and functions and one of the sphingolipid metabolites, sphingosine-1-phosphate (S1P), influences the differentiation and responsiveness of mast cells, which are best known to trigger IgE-dependent / independent allergic diseases like asthma and chronic obstructive pulmonary disease (Saluja et al., 2017). S1P level in BALF has been found to be significantly increased from subjects with asthma compared with the normal control (Ammit et al., 2001). The biosynthesis of sphingolipids initiates in the endoplasmic reticulum where serine palmitoyl transferase condenses serine and palmitoyl-CoA to generate 3-ketosphinganine, which is rapidly reduced to form sphinganine. Sphinganine is further converted into ceramides, which serve as a substrate for the production of sphingomyelins, gangliosides and sphingosine (Fyrst and Saba, 2010). S1P is derived from sphingosine through phosphorylation by two sphingosine kinases (SphK1 and SphK2), which are widely expressed in bronchial epithelium and airway smooth muscle cells while S1P can be irreversibly degraded by S1P lyase into ethanolamine phosphate and trans-2-hexadecenal (Fyrst and Saba, 2010). In this study, the levels of serine, sphinganine and ethanolamine phosphate in the OVA model were significantly decreased compared with those of the normal control group. Importantly, with treatment of AST using TWDS, the levels of serine, sphinganine and ethanolamine phosphate were upregulated back to the level of the normal control group. However, administration of DSP did not affect significantly this pathway.



(caption on next page)

**Fig. 5.** Results of metabolomics study, (a) PCA score plot (i) + ESI mode, (ii) –ESI mode (▲ AST using TWDS group), (● DSP group), (▼ OVA model group), (■ control group) and (\* QC); (b) (i) OPLS-DA score plot and (ii) S-plots of serum samples collected from the normal control and the OVA model groups based on UPLC-QTOF-MS acquired in positive ionization mode [ $R^2X = 0.327$ ,  $R^2Y = 0.983$ ,  $Q^2 = 0.746$ ] (iii) OPLS-DA score plot and (iv) S-plots of serum samples collected from the normal control and the OVA model groups based on UPLC-QTOF-MS acquired in negative ionization mode [ $R^2X = 0.416$ ,  $R^2Y = 0.976$ ,  $Q^2 = 0.770$ ], Red squares highlighted in (ii) were variable with VIP > 1.5; (c) (i) PLS-DA score plot and (ii) loading plot of PLS-DA of serum samples from the normal control, OVA model, DSP and AST using TWDS groups based on UPLC-QTOF-MS in acquired positive ionization mode (iii) PLS-DA score plot and (iv) loading plot of PLS-DA of serum samples from the normal control, OVA model, DSP group and AST using TWDS groups based on UPLC-QTOF-MS in acquired negative ionization mode. Red squares highlighted in (ii) were variable with VIP > 1.5.

OVA-induced allergic asthma caused serious disturbance to amino acid metabolism in our study. The levels of alanine and valine in the OVA group were upregulated and these trends are consistent with trends observed in previous literatures (Yu et al., 2016; Su et al., 2017). Treatment of AST using TWDS could downregulate these two amino acids back to the normal control level.

Odd chain phospholipids including LysoPC (17:0) and LysoPC (19:0) were uniquely detected in serum and both have been suggested to be bacterial in origin. With the treatment of AST using TWDS, the levels of these two metabolites were regulated back to the normal level. However, our preliminary microbiota results found that there were no significant differences among all groups. In recent year, those odd phospholipid species have been found to be present in both plant and mammalian species (Rezanka and Sigler, 2009). They are also associated with some diseases such as cardiovascular and peroxisomal disorders due to  $\alpha$ -oxidation (Jenkins et al., 2015).

Based on the findings deduced from non-target metabolomics, some follow-up works about the anti-inflammatory mechanism on lung tissue were carried out to elucidate the underlying signaling transduction pathway. NF- $\kappa$ B signaling pathway was proved to be closely associated with the development and progression of inflammation. Our results showed that the phosphorylation of p65 and I $\kappa$ B in the lung tissue were significantly decreased after treatment of AST using TWDS. For the reason above, the levels of cytokines including IL-4, IL-5, IL-13 and IgE

in serum were close to those of the guinea pigs with DSP administration.

ORMDL3 and the associated 17q21 locus have been found as contributors of the genetic susceptibility and underlying pathogenesis of asthma through genome-wide association studies (Moffatt et al., 2007). The functions of ORMDL3 are not fully understood and it is known to be involved in sphingolipid metabolism and de novo sphingolipid synthesis. From our results obtained, the gene expression of ORMDL3 of lung tissue in OVA model group were also significantly increased, compared with the normal control group. However, with the administration of DSP and treatment of AST using TWDS, the level of gene expression of ORMDL3 was downregulated back to the normal control. It was clearly indicated that treatment of AST using TWDS could inhibit the sphingolipid metabolism by downregulating the level of ORMDL3 in asthmatic guinea pigs.

Finally, the chemical constituents of TWDS used in this study were further explored by UPLC-orbitrap-MS and a total of 50 chemical markers, including organic acids, phenolic and its glycosides and alkaloids, were tentatively identified. Many of these compounds have been reported to possess anti-inflammatory activity. For example, sinapic acid exerted anti-inflammatory effects in vivo by inhibiting NF- $\kappa$ B activation in macrophages, thereby inhibiting the production of iNOS, COX-2, and pro-inflammatory cytokines (Yun et al., 2008). Sesamin decreased OVA-induced secretion of IgE and cytokines, prevented

**Table 3**

Trend of changes in metabolites identified by UPLC-ESI-QTOF-MS.

| Metabolites                             | Retention time (min) | Adducts                               | Theoretical m/z | Detected m/z | Mass error (ppm) | Fold Change     |               |               | p value of one-way ANOVA compared to Model group |       |        | VIP value of OPLS-DA |
|-----------------------------------------|----------------------|---------------------------------------|-----------------|--------------|------------------|-----------------|---------------|---------------|--------------------------------------------------|-------|--------|----------------------|
|                                         |                      |                                       |                 |              |                  | Model / Control | DSP / Control | AST / Control | Control                                          | DSP   | AST    |                      |
| Epinephrine <sup>#</sup>                | 0.89                 | [M + H] <sup>+</sup>                  | 184.0968        | 184.0969     | −7.06            | 1.95            | 0.45          | 0.62          | 0.008                                            | 0.097 | 0.042  | 1.58                 |
| Valine <sup>#</sup>                     | 0.89                 | [M + H] <sup>+</sup>                  | 118.0863        | 118.0867     | 3.39             | 0.46            | 0.85          | 1.00          | 0.024                                            | 0.195 | 0.032  | 1.33                 |
| Norepinephrine                          | 0.93                 | [M-H <sub>2</sub> O + H] <sup>+</sup> | 152.0706        | 152.0687     | −12.5            | 1.68            | 1.85          | 1.58          | 0.32                                             | 0.979 | 0.993  | 1.39                 |
| Xanthine <sup>#</sup>                   | 2.11                 | [M + H] <sup>+</sup>                  | 153.0407        | 153.0410     | 1.96             | 0.33            | 0.16          | 0.99          | 0.012                                            | 0.818 | 0.009  | 1.97                 |
| Androstenedione <sup>#</sup>            | 6.21                 | [M + H] <sup>+</sup>                  | 287.2006        | 287.2008     | 0.70             | 2.95            | 2.40          | 3.33          | 0.022                                            | 0.86  | 0.908  | 1.49                 |
| HEPE <sup>#</sup>                       | 11.36                | [M-H <sub>2</sub> O + H] <sup>+</sup> | 301.2168        | 301.2163     | −1.66            | 8.02            | 2.01          | 2.37          | 0.001                                            | 0.008 | 0.006  | 2.08                 |
| Stearidonic Acid <sup>#</sup>           | 14.29                | [M + H] <sup>+</sup>                  | 277.2162        | 277.2166     | 1.44             | 2.76            | 0.43          | 0.70          | 0.042                                            | 0.013 | 0.011  | 1.24                 |
| LysoPC (20:3) <sup>#</sup>              | 14.57                | [M + H] <sup>+</sup>                  | 546.3554        | 546.3557     | 0.55             | 0.44            | 0.95          | 1.13          | 0.044                                            | 0.68  | 0.012  | 1.12                 |
| Sphinganine <sup>#</sup>                | 15.22                | [M-H <sub>2</sub> O + H] <sup>+</sup> | 284.2948        | 284.2947     | −0.35            | 0.27            | 0.37          | 0.96          | 0.029                                            | 0.982 | 0.031  | 1.67                 |
| LysoPC (17:0) <sup>#</sup>              | 16.20                | [M + H] <sup>+</sup>                  | 510.3554        | 510.3561     | 1.37             | 0.28            | 0.79          | 1.16          | 0.03                                             | 0.161 | 0.008  | 1.18                 |
| LysoPC (20:2) <sup>#</sup>              | 16.47                | [M + H] <sup>+</sup>                  | 548.3711        | 548.3712     | 0.18             | 0.22            | 0.66          | 1.55          | 0.02                                             | 0.327 | <0.001 | 1.69                 |
| HETE <sup>#</sup>                       | 17.62                | [M + Na] <sup>+</sup>                 | 343.2244        | 343.2246     | 0.58             | 0.41            | 0.50          | 0.89          | 0.003                                            | 0.992 | 0.019  | 1.1                  |
| LysoPC (18:0) <sup>#</sup>              | 17.69                | [M + H] <sup>+</sup>                  | 524.3711        | 524.3713     | 0.38             | 0.47            | 0.91          | 1.28          | 0.047                                            | 0.152 | 0.002  | 1.19                 |
| Leukotriene B <sub>4</sub> <sup>#</sup> | 17.78                | [M-H <sub>2</sub> O + H] <sup>+</sup> | 319.2268        | 319.2245     | −7.20            | 2.53            | 0.74          | 0.89          | 0.015                                            | 0.005 | 0.009  | 1.89                 |
| LysoPC (20:1) <sup>#</sup>              | 18.00                | [M + H] <sup>+</sup>                  | 550.3867        | 550.3869     | 0.36             | 0.42            | 0.73          | 1.08          | 0.02                                             | 0.424 | 0.012  | 1.74                 |
| LysoPC (19:0) <sup>#</sup>              | 18.67                | [M + H] <sup>+</sup>                  | 538.3867        | 538.3873     | 1.11             | 0.30            | 0.51          | 1.23          | 0.004                                            | 0.371 | 0.001  | 1.97                 |
| Serine <sup>#</sup>                     | 0.82                 | [M - H] <sup>−</sup>                  | 104.0353        | 104.0352     | −0.96            | 0.46            | 0.67          | 0.86          | 0.004                                            | 0.456 | 0.047  | 1.27                 |
| Alanine <sup>#</sup>                    | 0.89                 | [M - H] <sup>−</sup>                  | 88.0404         | 88.0401      | −3.41            | 2.64            | 2.35          | 1.02          | <0.001                                           | 0.863 | 0.001  | 1.77                 |
| Xanthine <sup>#</sup>                   | 2.11                 | [M - H] <sup>−</sup>                  | 151.0261        | 151.0249     | −7.95            | 0.25            | 0.38          | 1.01          | 0.029                                            | 0.967 | 0.028  | 1.30                 |
| Glycocholic acid <sup>#</sup>           | 7.22                 | [M - H] <sup>−</sup>                  | 464.3018        | 464.301      | −1.72            | 4.98            | 2.71          | 1.75          | 0.023                                            | 0.283 | 0.041  | 1.25                 |
| Phosphoethanolamine <sup>#</sup>        | 15.22                | [M - H] <sup>−</sup>                  | 140.0118        | 140.0106     | −8.57            | 0.36            | 0.64          | 1.07          | 0.022                                            | 0.575 | 0.007  | 1.10                 |
| Eicosapentaenoic acid <sup>#</sup>      | 16.32                | [M - H] <sup>−</sup>                  | 301.2173        | 301.2163     | −3.32            | 0.40            | 0.33          | 1.01          | 0.017                                            | 0.982 | 0.011  | 1.29                 |
| LysoPC20:2 <sup>#</sup>                 | 16.49                | [M + FA-H] <sup>−</sup>               | 592.3620        | 592.3614     | −1.01            | 0.23            | 0.77          | 1.03          | 0.038                                            | 0.069 | 0.032  | 1.32                 |
| LysoPC16:0 <sup>#</sup>                 | 17.61                | [M - CH <sub>3</sub> ] <sup>−</sup>   | 480.3096        | 480.3092     | −0.83            | 0.45            | 0.85          | 1.48          | 0.034                                            | 0.243 | <0.001 | 2.11                 |
| HETE <sup>#</sup>                       | 17.64                | [M - H] <sup>−</sup>                  | 319.2279        | 319.2271     | −2.51            | 0.35            | 0.37          | 1.03          | 0.016                                            | 0.982 | 0.002  | 1.05                 |
| C22:5 <sup>#</sup>                      | 17.9                 | [M - H] <sup>−</sup>                  | 329.2486        | 329.2481     | −1.52            | 0.28            | 0.21          | 0.98          | 0.034                                            | 0.992 | 0.030  | 1.31                 |
| LysoPC20:1 <sup>*</sup>                 | 18                   | C20:1                                 | 309.2799        | 309.2799     | 0.00             | 0.52            | 0.80          | 1.41          | 0.004                                            | 0.213 | 0.021  | 1.10                 |

One-way (ANOVA): \*Tamhane's T2; #Tukey HSD post-hoc test.

eosinophil infiltration, and attenuated mucus oversecretion via the mechanism of decreasing phosphorylation levels of I $\kappa$ B- $\alpha$  and inhibiting NF- $\kappa$ B signaling pathways (Lin et al., 2014). Wogonin could alleviate airway inflammation through inhibition of STAT6 induced by Th2 cytokines in vivo (Ryu et al., 2015). Baicalein treatment reduced airway epithelial injury, ameliorated mitochondrial dysfunction and various features of airway inflammation in a mouse model of asthma (Mabalarajan et al., 2013). Berberine exerted dose-dependent ameliorative effects on OVA-induced airway inflammation via the inhibition of the NF- $\kappa$ B signaling pathway in a rat model of asthma (Li et al., 2016). Thus, based on the chemical profiling of TWDS obtained, the pharmacological effects of TWDS may be a synergy of actions of multi-components. Further studies are needed to elucidate the lung-protective molecular mechanisms of TWDS in detail.

## Conclusion

The present study confirmed that treatment of AST using TWDS had a markedly protective effect against OVA-induced allergic asthma in the guinea pig. This treatment not only attenuated airway inflammation and collagen deposition in the airway, but also decreased the levels of IL-4, IL-5, IL-13 and IgE in serum. In addition, metabolomics results showed that phospholipid, sphingolipid, purine, amino acid metabolisms and the level of epinephrine were restored back to the normal level. Results of the gene expression of ORMDL3 in lung tissues indicated that AST using TWDS could alter the sphingolipid metabolism by downregulating the level of ORMDL3. Moreover, western blotting analysis demonstrated that its anti-inflammatory mechanism was by decreasing the phosphorylation of p65 and I $\kappa$ B. Therefore, treatment of AST using TWDS could be a promising alternative for treating allergic asthma patients.

Author Contributions: S.J. Xiang and M.H. Li contributed equally to this work. S.J. Xiang, W.F. Wu, S.W. Cao, S.F. Ruan, Z.X. Wang and L.D. Weng performed the animal study, S.J. Xiang, Q. Shen, B.C. An, H.X. Zhu, and H.J. Chen performed the biological testing. M.H. Li performed the metabolomics work. M.H. Li, S.B. Chen, Y. Zhang and C.O. Chan analyzed and interpreted the metabolomics data. A.C.Y. Yuen and H.H. Tang performed the orbitrap mass spectrometer experiment. C.O. Chan, S.J. Xiang and M.H. Li prepared the first draft of the manuscript. M.Y.M. Wong overviewed all mass spectrometer data. Q. Liu and D.K.W. Mok designed and supervised the whole study and reviewed the manuscript.

## Conflicts of interest

We declare no conflict of interest

## Acknowledgments

This study was supported by the National Natural Science Foundation of China (81373975, 81303203, 81503222 and 81774329), the Hong Kong Chinese Material Medica Standards Project (HKCMMS), the Shenzhen Basic Research Program (JCYJ20151030164008764, JCYJ20160229173844278, JCYJ20160330171116798, JCYJ20140819153305694), Natural Science Foundation of Shanghai (17ZR1430800), and Longhua Medical Innovation Team Program (LYCX-01). We are also very grateful for the Large Equipment Funds and the University Research Facility in Chemical and Environmental Analysis of the Hong Kong Polytechnic University for providing the instruments used in this study. We sincerely thank Miss Josephine Leung for proofreading our manuscript.

## Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.phymed.2018.09.021.

## Reference

- Aalderen van, W.M., Postma, D.S., Koëter, G.H., Knol, K., 1991. Nocturnal airflow obstruction, histamine, and the autonomic central nervous system in children with allergic asthma. *Thorax* 46, 366–371.
- Ammit, A.J., Hastie, A.T., Edsall, L.C., Hoffman, R.K., Amrani, Y., Krymskaya, V.P., Kane, S.A., Peters, S.P., Penn, R.B., Spiegel, S., Panettieri Jr., R.A., 2001. Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma. *Faseb J.* 15, 1212.
- Barnes, P., FitzGerald, G., Brown, M., Dollery, C., 1980. Nocturnal asthma and changes in circulating epinephrine, histamine, and cortisol. *N. Engl. J. Med.* 303, 263–267.
- Bates, M.E., Clayton, M., Calhoun, W., Jarjour, N., Schrader, L., Geiger, K., Schultz, T., Sedgwick, J., Swenson, C., Busse, W., 1994. Relationship of plasma epinephrine and circulating eosinophils to nocturnal asthma. *Am. J. Respir. Crit. Care Med.* 149, 667–672.
- Bosnjak, B., Stelzmueller, B., Erb, K.J., Epstein, M.M., 2011. Treatment of allergic asthma: modulation of Th2 cells and their responses. *Respir. Res.* 12, 114.
- Busse, W.W., Lemanske Jr., R.F., 2001. Asthma. *N. Engl. J. Med.* 344, 350–362.
- Chini, L., Monteferrario, E., Graziani, S., Moschese, V., 2014. Novel treatments of asthma and allergic diseases. *Paediatr. Respir. Rev.* 15, 355–362.
- Davis, C.W., Dickey, B.F., 2015. Regulated airway goblet cell mucin secretion. *Annu. Rev. Physiol.* 70, 487–512.
- Delgadocharro, M.B., Guy, R.H., 2014. Effective use of transdermal drug delivery in children. *Adv. Drug Deliv. Rev.* 73, 63–82.
- Esther Jr., C.R., Coakley, R.D., Henderson, A.G., Zhou, Y.H., Wright, F.A., Boucher, R.C., 2015. Metabolomic evaluation of neutrophilic airway inflammation in cystic fibrosis. *Chest* 148, 507–515.
- Finkelman, F.D., Hogan, S.P., Hershey, G.K.K., Rothenberg, M.E., Wills-Karp, M., 2010. Importance of cytokines in murine allergic airway disease and human asthma. *J. Immunol.* 184, 1663–1674.
- Fyrst, H., Saba, J.D., 2010. An update on sphingosine-1-phosphate and other sphingolipid mediators. *Nat. Chem. Biol.* 6, 489–497.
- Gilfillan, A.M., Tkaczyk, C., 2006. Integrated signalling pathways for mast-cell activation. *Nat. Rev. Immunol.* 6, 218–230.
- Gorrochategui, E., Jaumot, J., Lacorte, S., Tauler, R., 2016. Data analysis strategies for targeted and untargeted LC-MS metabolomic studies: Overview and workflow. *TrAC Trends Anal. Chem.* 82, 425–442.
- Jenkins, B., West, J.A., Koulman, A., 2015. A review of odd-chain fatty acid metabolism and the role of pentadecanoic Acid (c15:0) and heptadecanoic Acid (c17:0) in health and disease. *Molecules* 20, 2425–2444.
- Jiao, H.Y., Su, W.W., Li, P.B., Liao, Y., Zhou, Q., Zhu, N., He, L.L., 2015. Therapeutic effects of naringin in a guinea pig model of ovalbumin-induced cough-variant asthma. *Pulm. Pharmacol. Ther.* 33, 59–65.
- Larché, M., Robinson, D.S., Kay, A.B., 2003. The role of T lymphocytes in the pathogenesis of asthma. *J. Allergy Clin. Immunol.* 111, 450–463.
- Li, Z.H., Zheng, J., Zhang, N., Li, C.D., 2016. Berberine improves airway inflammation and inhibits NF- $\kappa$ B signaling pathway in an ovalbumin-induced rat model of asthma. *J. Asthma* 53, 999–1005.
- Lin, C.H., Shen, M.L., Zhou, N., Lee, C.C., Kao, S.T., Wu, D.C., 2014. Protective effects of the polyphenol sesamin on allergen-induced TH2 responses and airway inflammation in mice. *PLoS One* 9, e96091.
- Liu, L., Liu, T., Li, G., Wang, Q., Ng, T., 2003. Isolation and determination of p-hydroxybenzoylcholine in traditional Chinese medicine Semen sinapis Albae. *Anal. Bioanal. Chem.* 376, 854–858.
- Lv, M.Y., Chen, J.Q., Gao, Y.Q., Sun, J.Q., Zhang, Q.Q., Zhang, M.H., Xu, F.G., Zhang, Z.J., 2015. Metabolomics based on liquid chromatography with mass spectrometry reveals the chemical difference in the stems and roots derived from Ephedra sinica. *J. Sep. Sci.* 38, 3331–3336.
- Ma, Y., Ge, A., Zhu, W., Liu, Y.N., Ji, N.F., Zha, W.J., Zhang, J.X., Zeng, X.N., Huang, M., 2016. Morin attenuates ovalbumin-induced airway inflammation by modulating oxidative stress-responsive MAPK signaling. *Oxidative Med. Cell. longev.* 2016, 5843672.
- Mabalarajan, U., Ahmad, T., Rehman, R., Leishangthem, G.D., Dinda, A.K., Agrawal, A., Ghosh, B., Sharma, S.K., 2013. Baicalein reduces airway injury in allergen and IL-13 induced airway inflammation. *PLoS One* 8, e62916.
- Manson, S.C., Brown, R.E., Cerulli, A., Vidaurre, C.F., 2009. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. *Respir. Med.* 103, 975–994.
- Moffatt, M.F., Kabesch, M., Liang, L., Dixon, A.L., Strachan, D., Heath, S., Depner, M., von Berg, A., Bufer, A., Rietschel, E., Heinzmann, A., Simma, B., Frischer, T., Willis Owen, S.A., Wong, K.C., Illig, T., Vogelberg, C., Weiland, S.K., von Mutius, E., Abecasis, G.R., Farrall, M., Gut, I.G., Lathrop, G.M., Cookson, W.O., 2007. Genetic variants regulating ormdl3 expression contribute to the risk of childhood asthma. *Nature* 448, 470–473.
- Morin, C., Fortin, S., Cantin, A.M., Rousseau, E., 2011. Docosahexaenoic acid derivative prevents inflammation and hyperreactivity in lung: implication of PKC-potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17kD in asthma. *Am. J. Respir. Cell Mol. Biol.* 45, 366–375.
- Morin, C., Fortin, S., Cantin, A.M., Rousseau, E., 2013. MAG-EPA resolves lung inflammation in an allergic model of asthma. *Clin. Exp. Allergy: J. Br. Soc. Allergy Clin. Immunol.* 43, 1071–1082.
- Nagana Gowda, G.A., Raftery, D., 2017. Recent advances in NMR-based metabolomics. *Anal. Chem.* 89, 490–510.
- Nials, A.T., Uddin, S., 2008. Mouse models of allergic asthma: acute and chronic allergen challenge. *Dis. Model Mech.* 1, 213.

- Pavord, I.D., Beasley, R., Agusti, A., Anderson, G.P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F.M., Fahy, J.V., Frey, U., Gibson, P., Heaney, L.G., Holt, P.G., Humbert, M., Lloyd, C.M., Marks, G., Martinez, F.D., Sly, P.D., Mutius von, E., Wenzel, S., Zar, H.J., Bush, A., 2017. After asthma: redefining airways diseases. *Lancet*. [https://doi.org/10.1016/S0140-6736\(17\)30879-6](https://doi.org/10.1016/S0140-6736(17)30879-6).
- Peng, J., Wu, X.Q., He, L.Y., Fang, y.g., Zi, M.J., Yan, S.Y., Liu, B.Y., 2012. Effects of summer acupoint application therapy in reducing exacerbation frequency of chronic lung diseases: protocol of a retrospective and prospective study. *J.Chin. Integr. Med.* 10, 39–47.
- Qiao, X., Li, R., Song, W., Miao, W.-j., Liu, J., Chen, H.-b., Guo, D.-a., Ye, M., 2016. A targeted strategy to analyze untargeted mass spectral data: rapid chemical profiling of *Scutellaria baicalensis* using ultra-high performance liquid chromatography coupled with hybrid quadrupole orbitrap mass spectrometry and key ion filtering. *J. Chromatogr. A* 1441, 83–95.
- Reinke, S.N., Gallart-Ayala, H., Gómez, C., Checa, A., Fauland, A., Naz, S., Kamleh, M.A., Djukanović, R., Hinks, T.S., Wheelock, C.E., 2017. Metabolomics analysis identifies different metabolotypes of asthma severity. *Eur. Respir. J.* 49, 1601740.
- Renauld, J.C., 2001. New insights into the role of cytokines in asthma. *J. Clin. Pathol.* 54, 577–589.
- Rezanka, T., Sigler, K., 2009. Odd-numbered very-long-chain fatty acids from the microbial, animal and plant kingdoms. *Prog. Lipid Res.* 48, 206–238.
- Rogers, D.F., 2007. Physiology of airway mucus secretion and pathophysiology of hypersecretion. *Respir. Care* 52, 1134.
- Ryu, E.K., Kim, T.H., Jang, E.J., Choi, Y.S., Kim, S.T., Hahm, K.B., Lee, H.J., 2015. Wogonin, a plant flavone from *Scutellariae radix*, attenuated ovalbumin-induced airway inflammation in mouse model of asthma via the suppression of IL-4/STAT6 signaling. *J. Clin. Biochem. Nutr.* 57, 105–112.
- Sagar, S., Akbarshahi, H., Uller, L., 2015. Translational value of animal models of asthma: challenges and promises. *Eur. J. Pharmacol.* 759, 272–277.
- Saluja, R., Kumar, A., Jain, M., Goel, S.K., Jain, A., 2017. Role of sphingosine-1-phosphate in mast cell functions and asthma and its regulation by non-coding rna. *Front. Immunol.* <https://doi.org/10.3389/fimmu.2017.00587>.
- Sarnes, E., Crofford, L., Watson, M., Dennis, G., Kan, H., Bass, D., 2011. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. *Clin. Ther.* 33, 1413–1432.
- Seddon, P., Bara, A., Lasserson, T.J., Ducharme, F.M., 2006. Oral xanthines as maintenance treatment for asthma in children. *Cochrane Database Syst. Rev.* 1 CD002885.
- Shu, X., Jiang, X.W., Cheng, B.C., Ma, S.C., Chen, G.Y., Yu, Z.L., 2016. Ultra-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry analysis of the impact of processing on toxic components of *Kansui Radix*. *BMC Complement. Altern. Med.* 16, 73.
- Su, L., Shi, L., Liu, J., Huang, L.F., Huang, Y., Nie, X.M., 2017. Metabolic profiling of asthma in mice and the interventional effects of SPA using liquid chromatography and Q-TOF mass spectrometry. *Mol. Biosyst.* 13, 1172–1181.
- Wen, H., Gao, H.-y., Qi, W., Xiao, F., Wang, L.-l., Wang, D., Yuan, D., 2014. Simultaneous determination of twenty-two components in *asari radix et rhizoma* by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. *Planta Medica* 80, 1753–1762.
- Wu, C.-Y., Kong, M., Zhang, W., Long, F., Zhou, J., Zhou, S.-S., Xu, J.-D., Xu, J., Li, S.-L., 2018. Impact of sulphur fumigation on the chemistry of ginger. *Food Chem.* 239, 953–963.
- Xiang, S.J., Chen, H.J., Zuo, T., Hong, J.H., Cao, S.W., Ruan, S.F., Weng, L.D., Zhu, H.X., Liu, Q., 2016. Effect of ‘treating winter disease in summer’ prescription on skin immune barrier and systemic immunity in a guinea pig model of asthma. *Int. J. Clin. Dermatol. Res.* 4, 81–86.
- Yu, M., Cui, F.X., Jia, H.M., Zhou, C., Yang, Y., Zhang, H.W., Ding, G., Zou, Z.M., 2016. Aberrant purine metabolism in allergic asthma revealed by plasma metabolomics. *J. Pharm. Biomed. Anal.* 120, 181–189.
- Yun, K.J., Koh, D.J., Kim, S.H., Park, S.J., Ryu, J.H., Kim, D.G., Lee, J.Y., Lee, K.T., 2008. Anti-inflammatory effects of sinapic acid through the suppression of inducible nitric oxide synthase, cyclooxygenase-2, and proinflammatory cytokines expressions via nuclear factor-kappaB inactivation. *J. Agric. Food Chem.* 56, 10265–10272.
- Zhang, L., 1990. *Zhang shi yi tong*. Shanghai Science Technology Publications Shanghai.
- Zhang, Z., Huang, Y., Tao, J., Li, Z., 2006. *Internal Medicine of Traditional Chinese Medicine*. Publishing House of Shanghai University Of Traditional Chinese Medicine, Shanghai.
- Zheng, X.J., Zheng, W.L., Zhou, J.J., Gao, X., Liu, Z.H., Han, N., Yin, J., 2017. Study on the discrimination between *Corydalis Rhizoma* and its adulterants based on HPLC-DAD-Q-TOF-MS associated with chemometric analysis. *J. Chromatogr. B*. <https://doi.org/10.1016/j.jchromb.2017.10.028>.
- Zhong, J., Chen, Y.F., Xie, W.J., Chen, L.J., 2009. Clinical study about curative effect of the crude herb moxibustion ointment. *Asia-Pac. Tradit. Med.* 5, 36–37.


## Supplementary document

Table 1

A summary of chemical contents in TWDS

| Name of herbal material | Name of chemical marker | Content (%) |
|-------------------------|-------------------------|-------------|
| Ephedra Herba           | Ephedrine hydrochloride | 0.83        |
| Sinapis Semen           | Sinapine thiocyanate    | 0.86        |
| Corydalis Rhizoma       | Tetrahydropalmatine     | 0.08        |
| Scutellariae Radix      | Baicalin                | 14.85       |
| Asari Radix et Rhizoma  | Asarinin                | 0.07        |

Figure 1



HPLC chromatogram of a) standard mixture of 1) ephedrine hydrochloride, 2) sinapine thiocyanate, 3) tetrahydropalmatine, 4) Baicalin and 5) Asarinin, b) TWDS prescription


#### In-house method

Extraction condition of TWDS: Accurately weighed 1g TWDS prescription powder samples were sonicated with 10mL methanol for 30 min. Then, the mixture was centrifuged at 14000 rpm at 4°C for 15 minutes. The solution was filtered through 0.45  $\mu$ m membrane filters prior to chemical analysis. Asarinin, ephedrine hydrochloride, tetrahydropalmatine, baicalin, sinapine thiocyanate were all dissolved in methanol (10mL) as mixed reference substances and being filtered by a 0.45 $\mu$ m membrane filter.


Condition of HPLC-DAD: Samples were analyzed by high-performance liquid chromatography (HPLC), equipped with a quaternary pump, diode array, and DAD detector, along with an analytical workstation(series 1260; Agilent, Wilmington, USA). Chromatographic separation was performed on HC-C<sub>18</sub> column (4.6nm $\times$ 250mm, 5 $\mu$ m, Agilent, USA) at 25°C. The mobile phase was composed of solvent A (acetonitrile) and solvent B (deionized water containing 0.1% phosphoric acid). The linear gradient elution was performed as follows: 5-24%A in 0–16min, 24-36%A in 16-30min, 36-69%A in 30-60min, 69-90%A in 60-80min, 90-95%A in 80-85min. The flow rate is 1.0mL/min. The detection wavelength was 250 nm. The sample injection volume was 10  $\mu$ l.

Figure 2.


Chemical structures of compounds identified in TWDS prescription by UPLC-ESI-Orbitrap-MS




42




45




48




43




46



44



47



49

